Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 263

recruiting
3 987
countries
28
conditions
2 109

4 235 trials match your criteria

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil

Nephrotic syndrome

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab and Mycophenolate Mofetil in Children with Idiopathic Nephrotic Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Obinutuzumab

Dementia Alzheimer's type

Not recruiting

Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)

Glomerulonephritis membranous

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab and Tacrolimus for Patients with Primary Membranous Nephropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Malignant mast cell neoplasm

Not recruiting

Study on the Safety and Effects of Livmoniplimab and Budigalimab in Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab

Rheumatoid arthritis

Not recruiting

Study on Rosnilimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab

Tourette's disorder

Not recruiting

Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Gemlapodect

Thrombotic microangiopathy

Not recruiting

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting

Study on the Effects and Safety of INZ-701 for Children with ENPP1 Deficiency

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1

Haemophilia A without inhibitors

Not recruiting

Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Emicizumab

Plasma cell myeloma

Not recruiting

Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.